Hikma Pharmaceuticals Share Discussion Threads

[mrthomas] 16/3/2016 11:50

Well brought in a month ago sitting on a loss but think this could be a long term hold

[broadwood] 16/3/2016 09:49

Upgrade.

Results seem pretty satisfactory looking forward.

Panmure Gordon Hikma Pharmaceuticals PLC 16/03/2016
Upgrades
Hold Buy
2
2,120.00 2,120.00 1,721.00
0

2

[chc15] 10/2/2016 15:42

lol, u ok now though, i got in below £17, back to normal now, mkts are mad!

[blueledge2] 10/2/2016 09:29

Well.
I brought at the wrong moment.

[broadwood] 29/12/2015 09:29

Probably a new year tip.

[coppertrader] 25/11/2015 10:44

Ben v sale sounds like good news. I beleive we only brought it for the equipment etc and have never moved in. Hopefully this will bolster the balance sheet somewhat.

[broadwood] 19/11/2015 11:56

Price action carrying over from yesterday's news.

[broadwood] 18/11/2015 08:12

Good news about the Portuguese facility.

Now for some strength.

[broadwood] 03/11/2015 15:30

() - Pharmaceuticals were on the newspaper pundits' agenda on Tuesday after Hikma Pharmaceuticals caused a bit of pain.
The FTSE 100 company warned on Monday that its generics division is performing below expectations due to slower-than-expected growth in sales for its gout treatment Mitigare. As a result, Hikma lowered guidance for that side of the business with projected revenues of around $150m, down from a previous range of $175m to $200m.

The Times' Tempus said the drug has had delays in getting to market, and the company has faced a legal challenge and aggressive pricing action from competitor Takeda. It noted that the delays push sales into the next financial year so it's not a disaster for the company, but the market doesn't like profit warnings.

However Tempus said that the trading update as a whole was positive, with two more products being rolled out. Analysts didn't help matters by moving down earnings forecasts by around seven percent, and the shares are selling on 23 times earnings. For that reason, it's advising traders avoid it for now.

[broadwood] 02/11/2015 08:16

Hikma Pharmaceuticals said most of its businesses have performed well in the year to date, although the generics division is currently below its expectations due to slower-than-expected growth in colchicine sales.
The company said it continues to see good demand for legacy products in the generics business. However, the need to shift towards a hybrid brand and generic strategy for its gout medicine, colchicine, has led to a more gradual growth rate in sales of the drug.

As a result, Hikma lowered guidance for the generics business to revenues of around $150m, down from a previous range of $175m to $200m.

It also said operating profit will fall, but this will be partly offset by the stronger performance in other parts of the business.

Hikma said the injectables business is continuing to perform very well, benefiting from its strong portfolio mix.

The branded business is also performing well across most markets, with growth in the year to date driven by a recovery in Saudi Arabia and other GCC markets, as well as strong growth in Egypt.

Chairman and chief executive officer Said Darwazah said: "We are delivering strong growth in most of our MENA markets in constant currency and achieving excellent profitability in our Injectables business whilst continuing to drive value from the legacy products in our generics business.

"We remain focused on penetrating the colchicine market and we are confident that we can successfully grow our market share in the coming year

[broadwood] 26/10/2015 15:48

Hikma Pharmaceuticals

Medicines play Hikma Pharmaceuticals (LSE: HIK) was also forced onto the back foot last week, the stock conceding 3% during the five-day trading period. In total the business has seen its share price fall an eye-popping 18% during the corresponding point in September, but I believe this weakness represents a terrific bargain-hunting opportunity.

Hikma is clearly on a strong upward trajectory thanks to the galloping popularity of its Branded and Injectables division, while recent acquisitions in the UK and US have significantly boosted its product suite and development pipeline. On top of this, the firm is doubling-down on its operations in critical emerging markets, exemplified by its licensing deal with over-the-counter giant Vitabiotics in August to sell its labels in the Middle East and North Africa. I fully expect revenues at Hikma to explode as we look down the line.

[coppertrader] 15/10/2015 11:41

Basilea Signs Distribution Deal For Zevtera In MENA Region With Hikma Pharma(RTTNews.com) - Switzerland'sBasilea Pharmaceutica Ltd. (BPMUF.PK) announced Thursday the signing of an exclusive distribution and supply agreement with Hikma Pharmaceuticals (HIK.L, HKMPY.PK) for Basilea's broad-spectrum antibiotic Zevtera (ceftobiprole medocaril) for the Middle East and North Africa or MENA region.Under the terms of the agreement, Hikma will have the exclusive right to register, distribute and market Zevtera across the MENA region. Basilea's European regulatory dossier will be the basis for regulatory filings in MENA countries. The financial terms of the agreement were not disclosed.Zevtera/Mabelio (European trade names of ceftobiprole, depending on the country) is a new generation broad-spectrum cephalosporin antibiotic with bactericidal activity against Gram-positive and Gram-negative bacteria associated with pneumonia, including methicillin-resistant Staphylococcus aureus or MRSA and susceptible Pseudomonas spp.Ceftobiprole has received national licenses for the treatment of adult patients with community- and hospital-acquired pneumonia, excluding ventilator-associated pneumonia in 13 European countries and Canada and has been launched in Germany, France, Italy and the United Kingdom.David Veitch, Basilea's Chief Commercial Officer, stated, "Hikma has a well-established and significant sales force with strong local presence and a successful track record of launching brands in this region. This agreement will potentially enable physicians and patients in the MENA region to benefit from a new option to treat severe bacterial infections."

[r ball] 21/9/2015 18:48

Encouraging.

[r ball] 08/9/2015 07:39

Resilient given that takeover "rumour" has diminished.

[coppertrader] 05/9/2015 22:07

West-Ward Pharmaceuticals Corp. is a wholly owned, U.S. subsidiary of Hikma Pharmaceuticals PLC, based in Amman, Jordan, and headquartered in London, England. Hikma (HIK.L) develops, manufactures, and markets a broad range of pharmaceutical products spanning 45 countries across the U.S., Europe, Middle East, and North Africa. The business is conducted through 3 segments: branded, injectables, and generics with 27 manufacturing facilities worldwide. Hikma's revenues for the year 2014 were nearly $1.5 billion globally.West-Ward is the U.S. operations arm of Hikma responsible for marketing, planning, and distributing products in both the injectable and non-injectable business units. West-Ward is supported by 6 FDA-approved manufacturing facilities across the globe, with two based in the U.S. West-Ward has grown at a rate faster than that of the consolidated company, increasing the importance of the U.S. market to Hikma. In 2014, West-Ward represented 51% of Hikma's group sales.West-Ward was established in 1946 as a generic orals manufacturing company. With over 60 years of experience, West-Ward has a longstanding presence in the U.S. oral solid generics market, with a focus on quality manufacturing and high service levels. West-Ward has a broad portfolio with 41 oral products in 103 dosage forms. Some of the products for the non-injectable product line include Doxycycline, Amoxicillin, and Prednisone.West-Ward became the second largest injectable supplier by volume in the U.S. after the acquisition of Baxter's Multi-Source Injectables (MSI) division in 2011. Continuing the growth of the injectables business, in 2014, Hikma/West-Ward announced the acquisition of certain assets of Bedford Laboratories (the generic sterile injectables division of Boehringer Ingelheim), thereby adding to its injectable product portfolio. In combination with the existing injectables portfolio and FDA manufacturing facilities in Portugal and Germany, these acquisitions solidified the portfolio and reinforced West-Ward as a full-service generics manufacturer. West-Ward's injectable product portfolio includes 65 products in 184 dosage forms and strengths, including controlled substances. Some of the injectable products include Fentanyl, Morphine, Phenylephrine, Glycopyrrolate and Argatroban.Spiro Gavaris (West-Ward vice president, sales and marketing) believes that on the heels of the Bedford transaction, West-Ward has optimized the potential of their combined product portfolio, building stronger customer relationships, and increasing new product launches and product acquisitions with the expanded operating capacity."Our expanded capacity and site transferring of products optimizes our outputs and increases production for flexible manufacturing," explains Gavaris.West-Ward is focused on continuous supply given the span of the global market shortages across the industry. With the acquisition of manufacturing facilities in Portugal, Jordan, Saudi Arabia, and Germany, Hikma/West-Ward has expanded its capacity to produce quality pharmaceuticals.For more information, visit www.west-ward.com.- See more at:

[broadwood] 03/9/2015 07:30

Barclays raised the stock’s target price from £20.50 to £27.60 owing the move to the “Roxane Revolution”. Analysts at the bank reckon Hikma’s deal to buy US specialty generics business Roxane from German drugmaker Boehringer Ingelheim will “transform its long-term growth profile”.


Simon Mather, of Barclays, said “Hikma has transformed its US exposure and long-term visibility through the $2.65bn acquisition of Roxane”. “It marks the second transaction between Hikma and Boehringer so begs the question what is next,” he added, highlighting the pharmaceutical company can still comfortably finance deals of up to $1bn in magnitude.


The acquisition will also bolster its product offerings, in particular in the respiratory sphere, and will allow it participate in lucrative first to file opportunities. Barclays was not alone in its praise of Hikma, Shore Capital also applauded the company’s management team for “the execution of its business model through timely and complementary acquisitions”.


Dr Brian White, of Shore Capital, noted “while we have been less enthusiastic regarding the outlook for the oral generics business, we concede that the recently announced acquisition of Roxane provides greater scale and sustainability”;. The positive stances from the brokers boosted the stock, closing

[broadwood] 02/9/2015 13:28

News) - Hikma Pharmaceuticals got a shot in the arm on Wednesday as Barclays lifted its price target on the stock to 2,760p from 2,050p.
The bank said Hikma has transformed its US exposure and long-term visibility through the $2.65bn acquisition of US specialty generics company Roxane.

"The closure of the deal transforms Hikma's presence in the US, its long-term growth trajectory, and the reliance on shortage drug opportunities," said Barclays.

"Boosting outer year earnings by over 20%, the deal revolutionises future opportunities, not only via portfolio-bolstering but also enabling lucrative paragraph IV and first-to-file opportunities."

Aside from the deal, it pointed to other significant sources of upside to its base-case assumptions, such as the accelerated transfer of Bedford products, the scope for cost savings and surprise product reintroductions.

Barclays said Jordan-based Hikma has a strong portfolio of branded products and with its high barriers to entry, the group is well positioned to benefit from the growing middle class.

Barclays rates the stock at 'overweight'

[discodave4] 02/9/2015 08:58

Only AHT, HIK on my watch list, waiting!.GLDD

[broadwood] 02/9/2015 08:49

Thanks DD. Hope you're in both aswell